On June 8-11, the 28th Annual Conference of the European Blood Association (2023 EHA) in 2023 was grandly held in Frankfurt, Germany in the form of a combination of online + offline!
As an international event in the field of hematology, EHA 2023 brings together the world's top hematology experts to share and discuss the cutting-edge research results in the field of hematology.
With the rapid development of hematology in China, more and more mainland scholars have appeared on the international stage, and a total of 21 achievements of the 2023 EHA Chinese Scholars Team have been selected into the Oral Presentations of the conference, making a loud voice in Chinese academia!
Acute lymphoblastic leukemia - clinical
Abstract number S113
Impact of IKZF1 Deletion In Relapsed and/or Refractory B-Cell Acute Lymphoblastic Leukemia Treated with CD19-Chimeric Antigen Receptor T-Cell Therapy
Effect of IKZF1 deletion on CD19 chimeric antigen receptor T (CAR-T) cell therapy for relapsed and/or refractory (R/R) acute B lymphoblastic leukemia (B-ALL).
speaker
Cai Zihong Southern Medical University Southern Hospital
Correspondence author
Zhou Hongsheng Southern Hospital, Southern Medical University
author
Zihong Cai, Ting Zhang, Suning Chen, Liang Huang, Qifa Liu, Hongsheng Zhou
Abstract number S116
Donor-Derived CD5 CAR T Cells for T-Cell Acute Lymphoblastic Leukemia
Donor-derived CD5 CAR-T cells for the treatment of T cell acute lymphoblastic leukemia
speaker
Pan Jing, Beijing Gao Boren Hospital
Correspondence author
Hu Guang Nanjing Reindeer Biotechnology Co., Ltd
author
Jing Pan, Yue Tan, Biping Deng, Zhuojun Ling, Jinlong Xu, Jiajia Duan, Zelin Wang, Kai Wang, Guang Hu
Chronic myeloid leukemia - clinical
Abstract number S158
Efficacy Of Low-Dose Tyrosine Kinase Inhibitor Therapy After Achieving Major Molecular Response In Persons With Chronic Myeloid Leukaemia
Efficacy of low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia after achieving a major molecular remission
speaker
Jiang Qian, Peking University People's Hospital
Correspondence author
Jiang Qian, Peking University People's Hospital
author
Zongru Li, Yijing Zhao, Linping Lu, Yong Guo, Ya-Zhen Qin, Qian Jiang
Clinical progression of myelodysplastic syndrome
Abstract number S171
Higher MDMX Expression was Associated with Hypomethylating Agent Resistance and Worse Survival in Myelodysplastic Syndrome Patients, Inferring it A Potential Therapeutic Target
Association between higher MDMX expression and low methylation drug resistance and poor survival in patients with myelodysplastic syndrome
speaker
Yu-Hung Wang Hospital affiliated to National Taiwan University School of Medicine
Correspondence author
Hwei-Fang Tien is a hospital attached to National Taiwan University School of Medicine
author
Yu-Hung Wang, Chien-Chin Lin, Chi-Yuan Yao, Kristian Gurashi, Fabio M. R. Amaral, Luciano Nicosia, Bettina Wingelhofer, Kiran Batta, Daniel Wiseman, Hsin-An Hou, Wen Chien Chou, Hwei-Fang Tien
Myeloproliferative neoplasms - clinical
Abstract number S212
A Randomized Double-Blind Phase 3 Study of Jaktinib versus Hydroxyurea in Patients with Intermediate-2 or High Risk Myelofibrosis
A randomized, double-blind phase 3 study of Jaktinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis
speaker
Zhang Yi The First Affiliated Hospital of Zhejiang University School of Medicine
Correspondence author
Jin Jie The First Affiliated Hospital of Zhejiang University School of Medicine
author
Yi Zhang, Hu Zhou, Junling Zhuang, Aili He, Yarong Li, Linhua Yang, Xin Du, Sujun Gao, Guangsheng He, Mei Hong, Qian Jiang, Zhongxing Jiang, Sun Kai, Lingling Yue, Cuiping Zheng, Zeping Zhou, Chenghao Jin, Hongmei Jing, Lin Liu, Qingchi Liu, Jishi Wang, Wen Wu, Yajing Xu, Dengshu Wu, Na Xu, Feng Zhang, Jin Zhang, Huanling Zhu, Zhijian Xiao, Jie Jin
Hodgkin lymphoma - clinical
Abstract number S216
CD47/PD-L1 Bispecific Antibody (IBI322) In Anti-PD-1 Or PD-L1 Treatment-Resistant Classical Hodgkin Lymphoma: A Phase Ⅰ Study
Use of CD47/PD-L1 bispecific antibody (IBI322) in classical Hodgkin lymphoma treated with anti-PD-1 or PD-L1: a phase I study
speaker
Jingwei Yu Tianjin Medical University Cancer Hospital
Correspondence author
Niu Ting, West China Hospital, Sichuan University
author
Huilai Zhang, Jingwei Yu, He Li, Wenbin Qian, Xibin Xiao, Qingqing Cai, Yao Liu, Yu Zhang, Liling Zhang, Ling Qin, Hui Zhou, Xiaoyi Tang, Yingmei Guo, Ting Niu
Aggressive non-Hodgkin lymphoma - clinical
Abstract number S324
Updated Clinical Results of First-in-Human Study of CD19/BCMA Dual-Targeting Fast CAR-T GC012F for Patients with Relapsed/Refractory B-Cell Non-Hodgkin' s Lymphoma
Recent clinical results of the first human study of CD19/BCMA dual-targeted rapid CAR-T GC012F in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
speaker
Zhang Yi The First Affiliated Hospital of Zhengzhou University
Correspondence author
Zhang Yi The First Affiliated Hospital of Zhengzhou University
author
Xinfeng Chen, Yu Ping, Ling Li, Lei Zhang, Xudong Zhang, Jianmin Huang, Jia Liu, Gui Li, Jiaping He, Hua Zhang, Wei Zhao, Lihong Weng, Wenjie Yin, Lianjun Shen, Wei William Cao, Wenling Li, Mingzhi Zhang, Yi Zhang
Stem Cell Transplantation - The Basics
Abstract number S240
Targeting PRMT1 Alleviates Chronic Graft-Versus-Host Disease By Reducing T and B Pathogenicity
Targeting PRMT1 mitigates the effects of chronic graft-versus-host disease by reducing malignant inheritance of T and B
speaker
Xiaoyan Zhao Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Correspondence author
Wang Huafang Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
author
Xiaoyan Zhao, Li Cai, Huafang Wang
Abstract number S241
Itaconate Inhibits Th1 Differentiation And Acute Graft-Versus-Host Disease Via Nrf2
Itaconate inhibits Th1 differentiation and acute graft-versus-host disease via Nrf2
speaker
Shen Yaoyao The First Affiliated Hospital of Soochow University
Correspondence author
Wu Depei The First Affiliated Hospital of Soochow University
author
Huanle Gong, Yaoyao Shen, Yang Xu, Depei Wu
Abstract number S243
Lactate Produced by T Cells During AGVHD Promotes Second Signal Generation for T Cell Activation Through Histone Modification
Lactic acid produced by T cells during AGVHD promotes the production of a second signal activated by T cells through histone modification
speaker
Hengwei Wu The First Affiliated Hospital of Zhejiang University School of Medicine
Correspondence author
Zhao Yanmin The First Affiliated Hospital of Zhejiang University School of Medicine
author
Hengwei Wu, Xin Jin, Fei Gao, He Huang, Yanmin Zhao
Stem Cell Transplantation - Clinical
Abstract number S246
JAK/ROCK Inhibitor TQ05105 for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Updated Results of A Phase 1B/2 Study
The JAK/ROCK inhibitor TQ05105 in the treatment of glucocorticoid-refractory or dependent chronic graft-versus-host disease: recent results from a Phase 1B/2 study
speaker
Huanghe The First Affiliated Hospital of Zhejiang University School of Medicine
Correspondence author
Huanghe The First Affiliated Hospital of Zhejiang University School of Medicine
author
Yanmin Zhao, Lifan Tu, Yi Luo, Jimin Shi, Yishan Ye, Jian Yu, Yi Yu, Shunqing Wang, Fankai Meng, Erlie Jiang, Xiaoyu zhu, Yang Yu, He Huang
Abstract number S247
Adding ruxolitinib and decitabine to BU/CY Conditioning Regimens to Prophylaxis Post-Transplant Relapse in High-Risk Aml Is Safe And Effective: A Prospective, Phase Ⅱ Study
The addition of ruxolitinib and decitabine to the BU/CY pretreatment regimen to prevent relapse after transplantation of high-risk AML is safe and effective: a prospective phase II study
speaker
Liu Daihong Chinese General Hospital of the People's Liberation Army
Correspondence author
Liu Daihong Chinese General Hospital of the People's Liberation Army
author
Yujun Wei, Kun Qian, Lili Wang, Fei Li, Nan Wang, Bo Peng, Yanan Wen, Lu Wang, Lingmin Xu, Xiangshu Jin, Liping Dou, Dai-Hong Liu
Abstract number S290
Development And Validation of A Prognostic Model of Bronchiolitis Obliterans Syndrome In Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
Development and validation of a prognostic model for adult patients with obliterative bronchitis syndrome after allogeneic hematopoietic stem cell transplantation
speaker
Huang Qiusha Peking University People's Hospital
Correspondence author
Zhang Xiaohui, Peking University People's Hospital
author
Qiu-Sha Huang, Tian-Xiao Han, Xiao-Lu Zhu, Hai-Xia Fu, Yun He, Feng-Rong Wang, Yuan-Yuan Zhang, Xiao-Dong Mo, Wei Han, Jing-Zhi Wang, Yu Wang, Huan Chen, Yu-Hong Chen, Chen-Hua Yan, Yuan Kong, Xiang-Yu Zhao, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang
thalassemia
Abstract number S271
An Updated Follow-Up Of BRL-101, CRISPR-CAS9-Mediated Gene Editing Of The BCL11A Enhancer For Transfusion-Dependent Beta-Thalasse
Latest update on BRL-101: CRISPR-CAS9-mediated gene editing of BCL11A extends the treatment of transfusion-dependent β-thalassemiaemia
speaker
Zheng Biao Shanghai Bangyao Biotechnology Co., Ltd
Correspondence author
Yuxuan Wu Shanghai Key Laboratory of Regulatory Biology
author
Bin Fu, Xinhua Zhang, Li Wang, Jiaoyang Liao, Shuanghong Chen, Biao Zheng, Wei Li, Fei Wang, Dali Li, Mingyao Liu, Yuxuan Wu
Abstract number S272
Safety and Efficacy of RM-001 In Patients With Transfusion-Dependent Β-Thalassemia: Early Results from the Ongoing of Autologous HBG1/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells
Safety and efficacy of RM-001 in patients with transfusion-dependent β-thalassemia: early results from autologous HBG1/2 promoter-modified CD34+ hematopoietic stem and progenitor cells
speaker
Liu Rongrong The First Affiliated Hospital of Guangxi Medical University
Correspondence author
Zhang Xinhua Chinese the 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army
author
Rongrong Liu, Li Wang, Hui Xu, Xiaolin Yin, Junbin Liang, Wenqiang Xie, Gaohui Yang, Yaoyun Li, Yali Zhou, Lei Shi, Bin Xiao, Lingling Shi, Zeyan Shi, Xuemei Zhou, Jianpei Fang, Xiangmin Xu, Yongrong Lai, Junjiu Huang, Xinhua Zhang
Enzymatic diseases, membrane diseases, and other anemias
Abstract number S275
PUS1 Regulates Erythropoiesis via Trna Pseudouridylation and Cytoplasmic Translation
PUS1 regulates erythropoiesis through TRNA pseudoacidification and cytoplasmic translation
speaker
Chu Yajing is a hospital of hematology, Chinese Academy of Medical Sciences
Correspondence author
Weiping Yuan Hospital of Hematology, Chinese Academy of Medical Sciences
author
Yajing Chu, Deyang Shi, Bichen Wang, Yu Lian, Haoyuan Li, Qiuyi Ma, Tong Liu, Mutian Cao, Jun Shi, Weiping Yuan
Bloodstream infections (including treatment and supportive care)
Abstract number S291
Long-Term Safety And Efficacy Of CMV/EBV-Specific T Cells for CMV and EBV Co-Reactivation After Haploidentical Stem Cell Transplantation
Long-term safety and efficacy of CMV/EBV-specific T cells for CMV and EBV co-activation after haploid stem cell transplantation
speaker
Pei Xuying Pei University People's Hospital
Correspondence author
Huang Xiaojun, Peking University People's Hospital
author
Pei Xuying, Xiangyu Zhao, Meng Lv, Jing Liu, Lanping Xu, Yu Wang, Xiao-Hui Zhang, Xiao-Jun Huang
Abstract number S293
A Novel Approach of Dual Metagenomics Next-Generation Sequencing for Early Diagnosis of Blood Stream Infection in Hematologic Patients with Febrile Neutropenia: a Multicenter, Prospective Study
A novel approach to bivariate genomics next-generation sequencing for the early diagnosis of bloodstream infections in patients with febrile neutropenia hematologic disorders: a multicenter, prospective study
speaker
Sun Yuqian, Peking University People's Hospital
Correspondence author
Huang Xiaojun, Peking University People's Hospital
author
Pei Xuying, Xiangyu Zhao, Meng Lv, Jing Liu, Lanping Xu, Yu Wang, Xiao-Hui Zhang, Xiao-Jun Huang
Platelet disease
Abstract number S295
Tacrolimus Modulates CD4+ T-Cell Proliferation and Function via MTHFD2 in Immune Thrombocytopenia
Tacrolimus regulates the proliferation and function of CD4+ T cells in immune thrombocytopenia via MTHFD2
speaker
Yang Liping, Peking University People's Hospital
Correspondence author
Zhang Xiaohui, Peking University People's Hospital
author
Li-Ping Yang, Hai-Xia Fu, Qiu-sha Huang, Peng Zhao, Chen-Cong Wang, Yuan-Yuan Zhang, Xiao-Jun Huang, Xiao-Hui Zhang
Abstract number S296
IL-1Β Signalling Induces, And Baricitinib Alleviates Neu1-Mediated Megakaryocyte Desialylation In Immune Thrombocytopenia
IL-1Beta signaling induction and Baricitinib alleviation of Neu1-mediated megakaryocytes demethylation in immune thrombocytopenia
speaker
Zhao Peng Peking University People's Hospital
Correspondence author
Zhang Xiaohui, Peking University People's Hospital
author
Peng Zhao, Zhuo-yu An, Hai-xia Fu, Hui-xin Liu, Li-ping Yang, Qing-yuan Qu, Qiu-sha Huang, Jin Wu, Ye-jun Wu, Yu-xiu Chen, Meng-lin Li, Chencong Wang, Xiaolu Zhu, Yun He, Juan-juan Li, Yuan-yuan Zhang, Qian Jiang, Hao Jiang, Jin Lu, Ying-jun Chang, Xiao-su Zhao, Xiang-yu Zhao, Xiao-jun Huang, Xiao-Hui Zhang
Bleeding disorders (congenital and acquired)
Abstract number S299
Orelabrutinib, An Irreversible Inhibitor of Bruton’S Tyrosine Kinase, for Treatment of Primary Immune Thrombocytopenia: Results of A Randomized, Open-Label Phase Ⅱ Study
Orelabrutinib, an irreversible Bruton tyrosine kinase inhibitor for the treatment of primary immune thrombocytopenia: a randomized, open-label, phase II study
speaker
Hou Ming, Qilu Hospital, Shandong University
Correspondence author
Hou Ming, Qilu Hospital, Shandong University
author
Yan Shi, Hu Zhou, Ruibin Huang, Fang Wang, Heng Mei, Lie Lin, Jingming Guo, Xin Zhou, Zhenyu Li, Yaorong Liu, Sichen Li, Wei Zhou, Ming Hou
The conference information is subject to the dynamic information on the official website
Click on the business card below to follow China Medical Tribune Blood Today
Identify the QR code to reply "stem cells" to win the physical book
Call for clinical questions in blood
386 views blood clinical questions? Ask anytime, anywhere
Follow + Star Blood Today
Looking forward to your next encounter